API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

2

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Arcus Biosciences

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Details:

AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor. It is being evaluated in phase 1 clinical trials in combination with zimberelimab and chemotherapy for the treatment of metastatic pancreatic cancer.

Lead Product(s): Quemliclustat,Zimberelimab,Paclitaxel

Therapeutic Area: Oncology Product Name: AB680

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2024

ASK
US

Upload
your Marketing & Sales content

Arcus Biosciences

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Details:

AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor. It is under phase 1 clinical development for the treatment of in combination with chemotherapy with or without zimberelimab for treatment-naïve metastatic pancreatic cancer.

Lead Product(s): Quemliclustat,Zimberelimab,Paclitaxel

Therapeutic Area: Oncology Product Name: AB680

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2024

ASK
US

Upload
your Marketing & Sales content

Arcus Biosciences

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

Details:

Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy.

Lead Product(s): Quemliclustat,Zimberelimab,Paclitaxel

Therapeutic Area: Oncology Product Name: AB680

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2021

ASK
US

Upload
your Marketing & Sales content